The Role of Bevacizumab in the Treatment of Radiation Necrosis in Children With Central Nervous System Tumors
Status:
Terminated
Trial end date:
2016-08-04
Target enrollment:
Participant gender:
Summary
This study is being done to learn about the safety of the study drug bevacizumab(Avastin®),
when used to treat radiation necrosis.
The primary objective of this study is to test the feasibility of treating Central Nervous
System (CNS) tumor patients suffering from radiation necrosis with bevacizumab every 2 weeks.
The secondary objectives of this study are:
- To evaluate improvement in neurologic symptoms associated with bevacizumab as assessed
by clinical evaluation;
- To investigate the neuro-imaging changes in radiation necrosis associated edema,
including Mass Resonance (MR) spectroscopy;
- To evaluate changes in corticosteroid use in patients with radiation necrosis following
treatment with bevacizumab;
- To evaluate changes in quality of life.